Skip to main content
SpringerLink
Log in

Does Rasagiline Have a Disease-Modifying Effect on Parkinson’s Disease?

  • Clinical Trial Report
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Effect of deprenyl on the progression of disability in early Parkinson disease. The Parkinson Study Group [no authors listed]. N Engl J Med 1989, 321:1364–1371.

    Google Scholar 

  2. Ahlskog JE, Uitti RJ: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction. Neurology 2010, 74:1143–1148.

    Article  CAS  PubMed  Google Scholar 

  3. Clarke CE: Are delayed-start design trials to show neuroprotection in Parkinson’s disease fundamentally flawed? Mov Disord 2008, 23:784–7789.

    Article  PubMed  Google Scholar 

  4. Schapira A, Albrecht S, Barone P, et al:. Immediate vs. delayed-start pramipexole in early Parkinson’s disease: the PROUD study. Parkinsonism Relat Disord 2009, 15:S2–S81.

    Google Scholar 

  5. D’Agostino RB Sr: The delayed start design. N Engl J Med 2009, 361:1304–1306.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Dr. Morgan has received consulting or speaking honoraria from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Pharmaceuticals. Dr. Mehta has received consulting or speaking honoraria from Allergan and Ipsen. Dr. Sethi has been a consultant to Teva Pharmaceuticals, Boehringer-Ingelheim, and Ipsen and has received honoraria and speaking fees from Teva Pharmaceuticals, Boehringer-Ingelheim, Ipsen, and GlaxoSmithKline.

Author information

Authors and Affiliations

  1. Movement Disorders Program, Medical College of Georgia, 1429 Harper Street, HF-1121, Augusta, GA, 30912, USA

    Shyamal H. Mehta, John C. Morgan & Kapil D. Sethi

Authors
  1. Shyamal H. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John C. Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kapil D. Sethi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kapil D. Sethi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mehta, S.H., Morgan, J.C. & Sethi, K.D. Does Rasagiline Have a Disease-Modifying Effect on Parkinson’s Disease?. Curr Neurol Neurosci Rep 10, 413–416 (2010). https://doi.org/10.1007/s11910-010-0133-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-010-0133-3

Keywords

Search

Navigation